Comparisons of Guideline-Recommended Therapies in Patients With Documented Coronary Artery Disease Having Percutaneous Coronary Intervention Versus Coronary Artery Bypass Grafting Versus Medical Therapy Only (from the REACH International Registry)

Benjamin A. Steinberg, BA, P. Gabriel Steg, MD, Deepak L. Bhatt, MD, Gregg C. Fonarow, MD, Uwe Zeymer, MD, and Christopher P. Cannon, MD, for the REACH Registry Investigators

To evaluate current compliance with recommendations for medical therapy in patients with coronary artery disease (CAD), the relation between previous revascularization and use of guideline-recommended therapies was investigated. From 5,400 outpatient practices in 44 countries, we compared baseline characteristics and medical therapy of 40,450 patients with documented CAD (all with previous myocardial infarction, percutaneous coronary intervention [PCI], coronary artery bypass grafting [CABG], or angina pectoris) by previous revascularization status. Approximately 33% of patients had previous CABG, 33% had previous PCI, and 33% had no previous revascularization. Patients with previous CABG were older and often men and diabetic. Patients with previous PCI were the youngest. Guideline-recommended medical therapy use was significantly higher in those with previous revascularization. Antiplatelet therapy in medically managed patients was 80% versus 86% and 91% for those with previous CABG or PCI, respectively. Use of any lipid-lowering agent in those with previous CABG or PCI was 86% in the 2 groups versus 70% in patients who were medically managed. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers were used in similar ratios among groups. Previous revascularization appears to be associated with better use of guideline-recommended medical treatment. These trends were similar for patients from the United States versus everywhere else. In conclusion, use of evidence-based, guideline-recommended therapies in outpatients with CAD needs to improve, especially in medically managed patients. © 2007 Elsevier Inc. All rights reserved. (Am J Cardiol 2007;99:1212–1215)

Methods and Results

The design of the REACH Registry has been described elsewhere. Briefly, it is an international registry done in 44 practices in 44 countries. We compared baseline characteristics and therapy use in patients with previous coronary revascularization. We stratified patients into those who had undergone PCI, CABG, or no revascularization. The extent to which these therapies are employed and in what settings remain unknown. To identify patterns of use for evidence-proven therapies in patients with known CAD (an indication for each of these therapies), we stratified patients in the REduction of Atherothrombosis for Continued Health (REACH) Registry by whether or not they had undergone coronary revascularization.

During the previous few decades, many new therapeutic agents have been methodically proved to decrease morbidity and mortality in patients with coronary artery disease (CAD). Drugs such as antiplatelet agents, β blockers, angiotensin-converting enzyme inhibitors, and statins have been shown to prevent myocardial infarction, stroke, and mortality. The professional guidelines have continued to evolve to reflect these advances and currently strongly recommend the use of these agents and others in patients with stable CAD and acute coronary syndromes. The extent to which these therapies are employed and in what settings remain unknown. To identify patterns of use for evidence-proven therapies in patients with known CAD (an indication for each of these therapies), we stratified patients in the REACH Registry by whether or not they had undergone coronary revascularization.

*Thrombolysis In Myocardial Infarction (TIMI) Study Group, Cardiovascular Division, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts; †Hôpital Bichat-Claude Bernard, Services de Cardiologie, Pairs, France; ¶Cleveland Clinic Foundation, Department of Cardiovascular Medicine, Cleveland, Ohio; ‡David Geffen School of Medicine, UCLA, Los Angeles, California; and ‡Herzcentrum Ludwigshafen, Medizinische Klinik II, Ludwigshafen, Germany. Manuscript received November 2, 2006; revised manuscript received and accepted December 7, 2006.

The REACH Registry is sponsored by Sanofi-Aventis, Paris, France; Bristol-Myers Squibb, New York, New York; and the Waksman Foundation, Tokyo, Japan. Dr. Cannon has received research grant support from Merck, AstraZeneca, Schering-Plough, and Accuminetics. He serves on advisory boards as a consultant with AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Merck, Schering-Plough, Pfizer, and Sanofi-Aventis. Dr. Bhatt has received honoraria for consulting on scientific advisory boards from AstraZeneca, Bristol-Myers Squibb, Eisai, Eli Lilly, GlaxoSmithKline, Millennium, Paringenix, PDL, Sanofi-Aventis, Schering Plough, The Medicines Company, and honoraria for lectures from Bristol-Myers Squibb, Sanofi-Aventis, and The Medicines Company. Dr. Fonarow has received research grants from GlaxoSmithKline, Pfizer, and Amgen. He is on the speaker’s bureau or has received honoraria from Sanofi-Aventis, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Merck, Schering-Plough, AstraZeneca, Amgen, and Biosite. He is a consultant for Sanofi-Aventis, GlaxoSmithKline, Pfizer, Merck, Schering-Plough, and Bristol-Myers Squibb. Dr. Zeymer has received research grants and honoraria for speaker bureau meetings from Bristol Myers Squibb, Sanofi Aventis, and Boehringer Ingelheim.

*Corresponding author: Tel: 617-278-0146; fax: 617-734-7329. E-mail address: cpcannon@partners.org (C.P. Cannon).
countries of patients affected by atherothrombosis with a focus on the outpatient setting. Baseline characteristics of the population have also been published.\textsuperscript{4} To qualify for entry in the registry, each patient had to be \(\geq 45\) years of age, sign informed consent, and have established CAD (\(n = 40,450\)), cerebrovascular disease (\(n = 18,992\)), peripheral arterial disease (\(n = 8,322\)), or \(\geq 3\) risk factors for atherothrombosis (\(n = 12,422\)). Exclusion criteria included current hospitalization, current participation in a clinical trial, or envisaged difficulties in attending follow-up. Entry occurred between 2003 and 2004.\textsuperscript{4} The present study was limited to patients with established CAD at a single point in time (after 1-year follow-up visit), yielding a minor discrepancy in total CAD population from that reported at baseline.\textsuperscript{4} Patients with CAD included a history of \(\geq 1\) of the following: stable angina (angina necessitating episodic or permanent use of medications), unstable angina, myocardial infarction, coronary angioplasty/stenting (percutaneous coronary intervention [PCI]), or coronary artery bypass graft (CABG) surgery (\(n = 40,450\)). Use of guideline-recommended therapies was stratified by previous revascularization procedure: those with a history of CABG (regardless of PCI history), those with a previous PCI but no CABG, and those with no history of any revascularization (medical management only). Medication use rates included all patients irrespective of contraindications/intolerance as captured by the registry. Patients in the United States were compared with those from the rest of the world. Results were compared using chi-square test with a 2-sided p value of 0.05 considered statistically significant.

Of the 68,236 patients in the registry, 40,450 had established CAD; 34\% (13,907) of these had a previous CABG,
32% (12,759) had a previous PCI only, and 34% (13,784) were managed medically with no history of revascularization. Of those patients with a history of CAGB, 69% (9,628) had no previous PCI, whereas 31% (4,279) also had a history of PCI. Those with a history of CAGB were older, more often men, and diabetic; patients with previous PCI were the youngest group. The largest proportion of women was in the group managed medically only (Table 1).

Use of guideline-recommended therapy was significantly greater in those with any previous revascularization (Table 2). However, in this population with established CAD, ~15% of patients with previous revascularization and >20% of those treated medically were not on any antiplatelet agent (including aspirin, adenosine diphosphate receptor antagonists, or dipyridamole). In addition, 15% to 20% were not on any lipid-lowering agent. Approximately 66% were on a β blocker and 66% were on an angiotensin-converting enzyme inhibitor or an angiotensin receptor blocker. These latter 2 agents were used in similar ratios among treatment groups and may not be indicated in every patient.5

Of the 4 evidence-based therapies in this population (antiplatelet agents, β blockers, inhibitors of the renin-angiotensin system, and statins or other lipid-lowering agents), 4 <40% received all 4, even in the better-treated groups of patients with a history of CAGB or PCI (Table 2). Patients receiving only “medical management” were least likely to receive all of the proved pharmacologic therapies, with <37% obtaining 3 of the 4 listed therapies and barely 25% receiving an antiplatelet agent, a β blocker, an inhibitor of the renin-angiotensin system, and a lipid-lowering agent.

Most patients (76%) in the United States had a history of some revascularization (11,722 of 15,399), whereas 60% of patients in the remaining countries underwent revascularization (14,944 of 25,051). There were no significant differences in trends of treatments for patients in the United States compared with those from the rest of the world (Table 3). The medically managed patients in each group were less likely to have received guideline-recommended therapies.

### Discussion

In this international registry subset of >40,000 patients with established CAD, previous revascularization appears to be associated with better use of guideline-recommended medical treatment. This is consistent with previous, smaller studies of local populations showing a direct correlation between invasive strategy for acute coronary syndrome and subsequent aggressive pharmacologic management.6,7 However, even in the best-treated groups not all patients received the therapies the guidelines recommended for them; better adherence to evidence-based therapies is necessary to manifest the expected decreases in morbidity and mortality.

The discrepancy in treatments between patients with previous revascularization and those managed medically seems contradictory: those patients with CAD managed only with medications appear to be receiving the fewest evidence-based pharmacologic treatments. Furthermore, the most basic therapies, antiplatelet agents, are undervalued by 10% to 20% across groups and used less in patients with a history of CAGB compared with those in the PCI group. Although further research is needed to determine for certain the reasons for this discrepancy, 2 possibilities exist: (1) treatment by cardiologists during and after revascularization...
procedures increases the likelihood of the use of guideline-recommended therapies for CAD and/or (2) having a revascularization procedure increases the awareness of the CAD diagnosis to the patients and their physicians, thus increasing prescriptions for and adherence to therapies.8

We also observed a dramatic gender imbalance with regard to revascularization, as barely 1/4 of those in the CABG or PCI groups were women (vs nearly 40% of those managed medically). Given previous reports suggesting that women are less likely to receive effective, aggressive, invasive management for acute coronary syndrome,9–13 these data warrant further investigation.

It is important to note that these analyses are limited by the fact that data on previous trials and subsequent discontinuation of medications are not available. Regardless of the reasons for inconsistencies in treatment rates, physicians need to be aware that patients with CAD without previous revascularization are less likely to receive treatments proved to decrease morbidity and mortality, particularly antiplatelet and lipid-lowering medications. In an era of evidence-based treatment and in a field ripe with clinical trials and undisputed evidence as to the efficacy of such treatments, use of guideline-recommended therapies needs to increase.


tional, prospective, observational investigation in subjects at risk for atherothrombotic events-study design. Am Heart J 2006;151(suppl):e1–e10.


